Press Releases

Date Title and Summary Additional Formats
Toggle Summary SAN DIEGO, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Read All » View HTML
Toggle Summary   Subject in Dose Cohort 2 Achieves Morphologic Leukemia-free State at Day 14 No Dose Limiting Toxicities Reported SAN DIEGO, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular Read All » View HTML
Toggle Summary Clinical Data from First Subjects in VOYAGE Study of FATE-NK100 for Acute Myelogenous Leukemia to be Presented at SITC 2017 First-of-Kind iPSC-derived Cancer Immunotherapy Candidates FT500 and FT819 to be Featured in Oral Presentations at 2017 ASH Annual Meeting First Subject Treated in Phase 2 Read All » View HTML
Toggle Summary Oral Presentation Unveiling Generation of CD8αβ + T Cells from Engineered Pluripotent Cell Line for Off-the-Shelf CAR T-Cell Cancer Immunotherapy Oral Presentation Highlighting GMP Production of iPSC-derived NK Cell Product Candidate FT500 to Support 1Q18 IND Filing Poster Presentation Releasing Read All » View HTML
Toggle Summary SAN DIEGO, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All » View HTML
Toggle Summary Independent Data Monitoring Committee Conducts Phase 1 Safety Review and Unanimously Recommends Opening of Phase 2 Enrollment First Seven Subjects Receiving ProTmune Clear Phase 1 Safety Objectives of Engraftment and Survival at Day 28 Phase 1 Day 100 Acute GvHD Data Expected to be Presented at Read All » View HTML
Toggle Summary SAN DIEGO, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company has appointed Jim Beitel, M.B.A. Read All » View HTML
Toggle Summary SAN DIEGO, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will be Read All » View HTML
Toggle Summary Patent Broadly Protects the Use of Prostaglandins for Enhancing Gene Transfer in Blood Stem Cells Read All » View HTML
Toggle Summary First Subject Treated with FATE-NK100 in VOYAGE for Acute Myelogenous Leukemia FDA Clears Investigational New Drug Applications for FATE-NK100 in Recurrent Ovarian Cancer and in Advanced Solid Tumors with Monoclonal Antibody Therapy Company Convenes PROTECT Data Monitoring Committee for ProTmune™ Read All » View HTML